After a 17-year hiatus in drug approvals for neurodegeneration, disease-modifying drugs for AD have finally broken the ice. With Lecanemab's clinically proven 30% reduction in...

Our core commitment centers on advancing R and D and Clinical Development strategies for TCR therapies, aiming to harness their immense potential in targeting solid tumors....